40
Participants
Start Date
March 1, 2024
Primary Completion Date
March 1, 2026
Study Completion Date
March 1, 2026
DEC3-VEN
Venetoclax in combination with decitabine (+-sorafenib) Venetoclax (VEN) 100mg d1, 200mg d2, 400mg d3-14 Decitabine (DEC) 20mg/m2/q8h, d4-6 (infusion time \>2h) Sorafenib 800mg/d, d8-14 (only for FLT3/ITD mutation positive patients)
The Second Affiliated Hospital of Kunming Medical University., Kunming
Chinese Academy of Medical Sciences
OTHER
Handan Central Hospital
OTHER
Taian City Central Hospital
OTHER
Tianjin People's Hospital
OTHER
Guizhou Provincial People's Hospital
OTHER
Central South University
OTHER
Western Theater General Hospital
UNKNOWN
First Affiliated Hospital of Guangxi Medical University
OTHER
Chengdu Jingdongfang Hospital
UNKNOWN
The Second Affiliated Hospital of Kunming Medical University
OTHER